Related Experiment Video
Updated: Jan 11, 2026
Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
Published on: February 23, 2024
Characteristics of ferritinophagy-related genes in chronic thromboembolic pulmonary hypertension, a study based on
Anqi Liu1, Jianping Wang2, Linfen Xi3
1Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 1000730, China; The Department of Radiology, China-Japan Friendship Hospital, Beijing, 100029, China.
Background:
Ferritinophagy plays a significant role in the development of cardiovascular diseases. The characteristics of ferritinophagy in chronic thromboembolic pulmonary hypertension (CTEPH) pathogenesis remains unknown. This study aims to identify ferritinophagy-related genes (FRGs) in CTEPH based on bioinformatics with machine learning model.
Methods:
The gene expression data of CTEPH and list of FRGs were downloaded from the Gene Expression Omnibus(GEO)database and GeneCards. CTEPH samples were stratified into distinct subtypes based on the expression levels of FRGs. Differences in immune characteristics and functional enrichment across different CTEPH subtypes were analyzed. Weighted gene co-expression network analysis (WGCNA) and machine learning algorithms were employed to identify hub genes among different subtypes, followed by the diagnostic model's construction based on the hub genes.
Results:
Based on FRGs, two distinct CTEPH subtypes were revealed, cluster A and cluster B, with significant disparities in pathway enrichment and immune microenvironment between two clusters. Notably, 24 differentially expressed genes were found between two clusters. Based on WGCNA and machine learning algorithms, seven genes were identified as hub genes. Finally, the diagnostic model based on these seven genes was established, which can distinguish the two subtypes well.
Conclusion:
This study underscores two FRG-based CTEPH subtypes characterized by unique immune profiles, offering a promising avenue for the development of subtype-specific, personalized therapeutic strategies for CTEPH patients.
